Search research articles
Contact Us
Filters
Showing results (41-50 of 103) with videos related to
Page
of 11
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
January 19, 2019
Effects of baseline symptom burden on treatment response in COPD
Fernando J Martinez, Roger A Abrahams, Gary T Ferguson, et al.
Respiratory Medicine
|
April 7, 2020
Goals of COPD treatment: Focus on symptoms and exacerbations
Claus F Vogelmeier, Miguel Román-Rodríguez, Dave Singh, et al.
Respiratory Medicine
|
January 21, 2023
Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease
James F Donohue, Gary T Ferguson, Jill A Ohar, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study
Gary T Ferguson, Angel Fowler Taylor, Chau Thach, et al.
Chest
|
July 20, 2017
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Fernando J Martinez, Leonardo M Fabbri, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 4, 2020
Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study
Gary T Ferguson, Tor Skärby, Lars H Nordenmark, et al.
Respiratory Medicine
|
December 13, 2017
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study
Gary T Ferguson, Donald P Tashkin, Tor Skärby, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
The European Respiratory Journal
|
September 18, 2018
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
Gary T Ferguson, Alberto Papi, Antonio Anzueto, et al.
Advances in Therapy
|
April 27, 2020
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β<sub>2</sub>-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
Gary T Ferguson, Patrick Darken, Shaila Ballal, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 103) with videos related to
Sort By:
Page
of 11
International Journal of Chronic Obstructive Pulmonary Disease
|
January 19, 2019
Effects of baseline symptom burden on treatment response in COPD
Fernando J Martinez, Roger A Abrahams, Gary T Ferguson, et al.
Respiratory Medicine
|
April 7, 2020
Goals of COPD treatment: Focus on symptoms and exacerbations
Claus F Vogelmeier, Miguel Román-Rodríguez, Dave Singh, et al.
Respiratory Medicine
|
January 21, 2023
Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease
James F Donohue, Gary T Ferguson, Jill A Ohar, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study
Gary T Ferguson, Angel Fowler Taylor, Chau Thach, et al.
Chest
|
July 20, 2017
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Fernando J Martinez, Leonardo M Fabbri, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 4, 2020
Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study
Gary T Ferguson, Tor Skärby, Lars H Nordenmark, et al.
Respiratory Medicine
|
December 13, 2017
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study
Gary T Ferguson, Donald P Tashkin, Tor Skärby, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
The European Respiratory Journal
|
September 18, 2018
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
Gary T Ferguson, Alberto Papi, Antonio Anzueto, et al.
Advances in Therapy
|
April 27, 2020
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β<sub>2</sub>-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
Gary T Ferguson, Patrick Darken, Shaila Ballal, et al.
Page
of 11